Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 6c, beats revenue
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $248.25 --0%
Revenue Growth %: +6.2%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
CCEL, SLP, TMQ, More
Revenue Growth %: +6.2%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
CCEL, SLP, TMQ, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $4.51, $0.06 better than the analyst estimate of $4.45. Revenue for the quarter came in at $957.32 million versus the consensus estimate of $941.99 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AZZ, Inc. (AZZ) Tops Q1 EPS by 16c, Offers Guidance
- Wolfe Research Upgrades Grainger (GWW) to Peerperform (correction)
- Wolfe Research Upgrades ITT Corp. (ITT) to Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
